Aimmune Therapeutics, Inc. (AIMT)


Stock Price Forecast

Oct. 12, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Aimmune Therapeutics, Inc. chart...

About the Company

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Sector

Health Technology

Industry

Biotechnology

Employees

275

$1M

Total Revenue

275

Employees

$2B

Market Capitalization

-7.68

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AIMT News

Aimmune Stock Halted as FDA Considers Peanut Allergy Treatment

4y ago, source: TheStreet.com

Aimmune Therapeutics is hlated as the FDA conducts an efficacy meeting on the company's peanut allergy treatment candidate Palforzia. Aimmune Therapeutics is hlated as the FDA conducts an efficacy ...

Search Results for "Aimmune Therapeutics":

6y ago, source: Investing

Aimmune Therapeutics, Inc. (NASDAQ:LGND) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Is AIMT going up? Or down?

Nestle to Acquire Peanuts Allergic Treatment Maker Aimmune Therapeutics for $2 Billion; Target Price CHF 120

3y ago, source: FXEmpire.com

Nestle SA, the world's largest food & beverage company, said it will completely acquire a biopharmaceutical company Aimmune Therapeutics, which has the first and only FDA-approved treatment to ...

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

13d ago, source: Morningstar

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome ... To report SUSPECTED ADVERSE REACTIONS, contact Aimmune Therapeutics at 1-833-AIM-2KNO (1-833-246-2566), or the FDA at 1-800 ...

Intellia Therapeutics Inc NTLA

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

EFTR eFFECTOR Therapeutics, Inc.

22h ago, source: Seeking Alpha

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...

CADL Candel Therapeutics, Inc.

2d ago, source: Seeking Alpha

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical ...

Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results

21d ago, source: Yahoo Finance

Warning! GuruFocus has detected 2 Warning Sign with DNLI. Denali Therapeutics Inc (NASDAQ:DNLI) released its 8-K filing on February 27, 2024, detailing its financial results for the fourth quarter ...

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

14d ago, source: Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and ...

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

14d ago, source: Nasdaq

Leverage the Nasdaq+ Scorecard to analyze stocks based on your investment priorities and our market data.

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

14d ago, source:

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...